Crosslinked Polymer Composition for High-Capacity Potassium Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hyperkalemia, such as ion-exchange resins and diuretics, are inadequate for outpatient use due to side effects and limited efficacy, necessitating a new drug with higher binding capacity for potassium ions.
Innovation Solution
A polymer with specific structural features, represented by formula (I), is developed for high potassium ion adsorption, which can be administered to reduce serum potassium levels and treat or prevent hyperkalemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ion-exchange resins are used for hyperkalemia treatment, then potassium binding capacity is improved, but gastrointestinal side effects and sodium excess increase
Solution Approach 1:
The patent modifies the chemical structure of ion-exchange resins by introducing specific functional groups (carboxyl, sulfonic acid, phosphonic acid) and controlling molecular weight (100-1000 Da) to enhance potassium binding capacity while reducing gastrointestinal irritation. The crosslinking degree is optimized to balance binding performance with GI tolerance.
Solution Approach 2:
The invention creates composite ion-exchange resin materials combining multiple functional groups (carboxyl, sulfonic acid, phosphonic acid) within a single polymer structure, allowing simultaneous optimization of potassium binding capacity and reduced sodium exchange, thereby minimizing gastrointestinal side effects.
2Productivity
If diuretics are used to eliminate sodium and potassium, then potassium excretion is improved, but nephropathy and diuretic resistance limit efficacy
Solution Approach 1:
The patent extracts the potassium binding function from the kidney (where diuretics act) and places it directly in the gastrointestinal tract through oral ion-exchange resins. This bypasses renal limitations and diuretic resistance, providing reliable potassium excretion independent of kidney function or diuretic efficacy.
Solution Approach 2:
The ion-exchange resin acts as an intermediary substance that facilitates potassium elimination through the gastrointestinal tract, mediating between dietary potassium intake and renal excretion. This intermediary mechanism overcomes diuretic resistance and nephropathy limitations.
3Quantity of substance
If diuretics are administered to reduce potassium, then potassium levels decrease, but blood pressure and volume drop in CHF patients
Solution Approach 1:
The patent segments the potassium elimination process from the blood pressure regulation pathway by using gastrointestinal ion-exchange resins instead of systemic diuretics. This allows independent control of potassium excretion without affecting blood pressure or volume status in CHF patients.
Solution Approach 2:
The ion-exchange resin serves as a selective intermediary that removes potassium from the body through the GI tract without interfering with cardiovascular homeostasis. This mediator approach enables potassium reduction in CHF patients without causing hypotension or volume depletion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer effectively binds and eliminates potassium ions in the gastrointestinal tract, reducing serum potassium levels and preventing hyperkalemia without significant side effects, offering a viable outpatient treatment option.
Implementation Method 1
Most of the existing therapeutic regimens forhyperkalemia are limited to hospitalization. Ion-exchange resins, such as Kayexalate, are not suitable for outpatients or long-term treatment
Implementation Method 2
Therefore, it is urgent to develop a new drug with higher binding capacity for treatinghyperkalemia
Data Source
AI summary
Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO3−), sulfuric acid group (—OSO3−), carboxylic group (—CO2−), phosphonic acid group (—OPO32−), phosphate group (—OPO32−), and sulfamic acid group (—NHSO3−). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.